Since ABT-737 targets both BCL-2 and BCL-XL, we investigated the contribution of both of these anti-apoptotic proteins to tumor cell viability by using specific inhibitors as single agents and in combination with GNE-493. The gene discussed is BCL2L1; the disease is neoplasm.